Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

JACI-35.054

Other

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is JACI-35.054?

JACI-35.054 is an investigational drug studied in Alzheimer's Disease, Cognitive Impairment, Tauopathies.

At a glance

Drug type
Other
Therapy area
Neurology
In trials of
ACIU
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04445831 Phase 1/2 Alzheimer's Disease Completed ACIU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's DiseaseBrain DiseasesCentral Nervous System DiseasesCognitive ImpairmentDementiaMild Cognitive ImpairmentTauopathies

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.